{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfaproxyline is a sulfonamide derivative patented by J. R. Geigy A.-G. as an antibiotic, useful in the treatment of urinary tract infections. In preclinical models, sulfaproxyline is effective against staphylococci infection in guinea pigs. Bisulfon D, a drug product comprising the combination of sulfaproxyline and sulfamerazine has been used for the treatment of urinary tract infections in the puerperium.
Status:
Investigational
Source:
INN:sulocarbilate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sulocarbilate (also known as W-1548-1) is a sulfanilamide derivative and carbonic anhydrase inhibitor with diuretic activity. In preclinical models, Sulocarbilate shows similar efficacy and superior safety profile compared to other agents of this type. Clinically, Sulocarbilate shows the maximum effect as a natriuretic agent in an oral daily dose of 2 g.
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulosemide is a sulfamoylorthanilic acid derivative patented by German chemicals then life-sciences company Hoechst A.-G. as salidiuretic agent.
Status:
Investigational
Source:
INN:terflavoxate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Terflavoxate is a benzopyran derivative patented by Recordati S. A. Chemical and Pharmaceutical Co. as a muscle relaxant, anesthetic, anti-inflammatory, and antispastic agent useful for the treatment of lower urinary tract disease. Terflavoxate inhibited by more than 50% field stimulation-induced contractions of rabbit bladder strips, indicates that mechanisms other than the anticholinergic one should be responsible for its smooth muscle relaxant properties.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Tiotidine is a controversial histamine H2 receptor ligand with negligible activity against H1- and H3- receptors. It was found that tiotidine behaves as an inverse agonist in U-937 cells, diminishing basal cAMP levels. Tiotidine showed two binding sites, one with high affinity and low capacity and the other with low affinity and high capacity. Tiotidine is currently in use as a radioligand in histamine H2-receptor binding studies. Compared to cimetidine, tiotidine appears to be approximately eight times more potent on a molar basis than cimetidine as an inhibitor of acid secretion, and the tiotidine effect is more prolonged. It was developed for the treatment of peptic ulcer.
Class (Stereo):
CHEMICAL (ACHIRAL)
Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to 5-HT2 (serotonin) receptors, alpha1 and alpha 2 adrenergic receptors, dopamine D2 receptors and histamine H1 receptors. Ocaperidone is an antagonist primarily at the 5HT and D2 receptors. A proposed mechanism of action is the central D2 receptor blockade which is common to all neuroleptics that are used to treat positive symptoms of schizophrenia.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Prisotinol is aminoalkyl-5-pyridinol patented by Ciba-Geigy A.-G. for treatment of angina pectoris. Prisotinol was studied in phase II clinical trials as a cardioprotective agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Prideperone is 5-Cyano-2-methoxy-benzamide derivative patented by Ciba-Geigy A.-G. as antipsychotic.
Status:
Investigational
Source:
NCT00543816: Phase 3 Interventional Terminated Diabetes Mellitus, Type 2
(2003)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
MK-0767 is a potent hypoglycaemic insulin sensitizer being evaluated by Kyorin with potential as an antidiabetic agent. MK-0767 acts as a dual agonist of the peroxisome proliferator-activated receptors alpha and gamma, induced high-affinity interactions of PPARα and PPARγ with the transcriptional coactivator CBP in vitro. In ob/ob mice, MK-0767 normalized hyperglycemia and hyperinsulinemia with equal or greater potency and efficacy than pioglitazone. Treatment of hamsters with MK-0767 produced substantial reductions in blood cholesterol and triglycerides. In dogs, MK-0767 reduced serum cholesterol levels with a potency more than 10-fold greater than simvastatin. The efficacies of MK-0767 and simvastatin were additive when given together.
Status:
Investigational
Source:
NCT00165802: Phase 1 Interventional Completed Cancer, Malignant Tumors
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
